Diagnosis, management, and treatment of hepatitis C (Q29620656)

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15057920

30 April 2017

0 references

1 reference

3

Thomas DL

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15057920

30 April 2017

author name string

Strader DB

series ordinal

1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15057920

30 April 2017

Wright T

series ordinal

2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15057920

30 April 2017

Seeff LB

series ordinal

4

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15057920

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15057920

30 April 2017

language of work or name

1 reference

30 April 2017

publication date

April 2004

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15057920

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15057920

30 April 2017

volume

39

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15057920

30 April 2017

issue

4

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15057920

30 April 2017

page(s)

1147-71

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15057920

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

30 April 2017

cites work

1 reference

Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis

21 January 2018

1 reference

Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study

21 January 2018

1 reference

The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse

21 January 2018

1 reference

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy

21 January 2018

1 reference

High Rate of Infectivity and Liver Disease in Blood Donors with Antibodies to Hepatitis C Virus

21 January 2018

1 reference

Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group

21 January 2018

1 reference

Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus

21 January 2018

1 reference

Hepatitis C virus (HCV) viremia in human immunodeficiency virus-seronegative and -seropositive patients with indeterminate HCV recombinant immunoblot assay

21 January 2018

1 reference

Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group

21 January 2018

1 reference

Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial

21 January 2018

1 reference

A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection

21 January 2018

1 reference

Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis

21 January 2018

1 reference

Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory

21 January 2018

1 reference

Fulminant hepatitis A in intravenous drug users with chronic liver disease.

21 January 2018

1 reference

American Gastroenterological Association policy statement on the use of medical practice guidelines by managed care organizations and insurance carriers

21 January 2018

1 reference

7 January 2021

Purpose of quality standards for infectious diseases. Infectious Diseases Society of America

1 reference

7 January 2021

The Expert Panel on Preventive Services: Continuing the Work of the U.S. Preventive Services Task Force

1 reference

7 January 2021

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

1 reference

7 January 2021

The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study

1 reference

7 January 2021

Risk of hepatitis C seroconversion after occupational exposures in health care workers*1

1 reference

7 January 2021

Beauty treatments and risk of parenterally transmitted hepatitis: results from the hepatitis surveillance system in Italy

1 reference

7 January 2021

Hepatitis C transmission by cosmetic tattooing in women

1 reference

7 January 2021

Shaving as potential source of hepatitis C virus infection

1 reference

7 January 2021

Transmission of hepatitis C in an isolated area in Japan: community-acquired infection. The South Kiso Hepatitis Study Group.

1 reference

7 January 2021

Epidemiology of Hepatitis C in the East

1 reference

7 January 2021

Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center

1 reference

7 January 2021

Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection

1 reference

7 January 2021

A case-control study of risk factors for sporadic hepatitis C virus infection in the southwestern United States

1 reference

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

7 January 2021

Diagnostic testing for hepatitis C.

1 reference

7 January 2021

What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories?

1 reference

7 January 2021

A long-term study of hepatitis C virus replication in non-A, non-B hepatitis

1 reference

7 January 2021

Hepatitis C virus RNA and antibody response in the clinical course of acute hepatitis C virus infection

1 reference

7 January 2021

Molecular diagnosis of viral hepatitis

1 reference

7 January 2021

Viral heterogeneity of the hepatitis C virus

1 reference

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

7 January 2021

Genotyping of hepatitis C virus isolates using CLIP sequencing

1 reference

7 January 2021

Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States

1 reference

7 January 2021

Clinical Evaluation of Two Methods for Genotyping Hepatitis C Virus Based on Analysis of the 5' Noncoding Region

1 reference

7 January 2021

Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection

1 reference

7 January 2021

The long-term pathological evolution of chronic hepatitis C.

1 reference

7 January 2021

Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C.

1 reference

7 January 2021

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

1 reference

7 January 2021

Histological grading and staging of chronic hepatitis

1 reference

7 January 2021

Factors predictive of a beneficial response to therapy of hepatitis C

1 reference

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

7 January 2021

Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population

1 reference

7 January 2021

Liver biopsy in chronic hepatitis C: routine or selective

1 reference

7 January 2021

A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase

1 reference

7 January 2021

The natural history of chronic hepatitis C infection.

1 reference

7 January 2021

Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

7 January 2021

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

1 reference

7 January 2021

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

7 January 2021

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

1 reference

7 January 2021

Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C

1 reference

7 January 2021

The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group

1 reference

7 January 2021

Intensive interferon therapy does not increase virological response rates in African Americans with chronic hepatitis C

1 reference

7 January 2021

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

1 reference

7 January 2021

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment

1 reference

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

7 January 2021

Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.

1 reference

7 January 2021

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

1 reference

7 January 2021

Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA.

1 reference

7 January 2021

Severity and correlates of liver disease in hepatitis C virus-infected injection drug users

1 reference

7 January 2021

Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV.

1 reference

7 January 2021

Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels.

1 reference

7 January 2021

Therapy of hepatitis C: Patients with normal aminotransferase levels

1 reference

7 January 2021

Changing epidemiologic pattern of chronic hepatitis C virus infection in Italian children

1 reference

7 January 2021

Non-A, non-B hepatitis in children: a clinical, histologic, and serologic study.

1 reference

7 January 2021

Cryptogenic chronic liver disease and hepatitis C virus infection in children

1 reference

7 January 2021

Interferon-alpha treatment of chronic hepatitis C virus infection in children

1 reference

7 January 2021

Hepatitis C virus infection and related liver disease in children of mothers with antibodies to the virus

1 reference

7 January 2021

Pathology of chronic hepatitis C in children. Child Liver Study Group of Japan

1 reference

7 January 2021

Histopathology of the liver in children with chronic hepatitis C viral infection

1 reference

7 January 2021

Chronic hepatitis C in children: the pathological and clinical spectrum.

1 reference

7 January 2021

Response to interferon therapy in children with chronic hepatitis C

1 reference

7 January 2021

High dosage alpha-interferon for treatment of children and young adults with chronic hepatitis C disease

1 reference

7 January 2021

An analysis of published trials of interferon monotherapy in children with chronic hepatitis C.

1 reference

7 January 2021

Impact of chronic hepatitis B and interferon-alpha therapy on growth of children

1 reference

7 January 2021

Influence of recombinant interferon alpha on nutritional status and growth pattern in children with chronic viral hepatitis

1 reference

7 January 2021

Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group

1 reference

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

7 January 2021

Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection

1 reference

7 January 2021

Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection

1 reference

7 January 2021

Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis

1 reference

7 January 2021

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

1 reference

7 January 2021

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

1 reference

7 January 2021

Human immunodeficiency virus infection, anemia, and survival

1 reference

7 January 2021

Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro

1 reference

7 January 2021

Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection

1 reference

7 January 2021

Mitochondrial toxic effects and ribavirin

1 reference

7 January 2021

Ribavirin antagonizes the effect of azidothymidine on HIV replication

1 reference

7 January 2021

Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report

1 reference

7 January 2021

Lack of interference between ribavirin and nucleosidic analogues in HIV/HCV co-infected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy

1 reference

7 January 2021

A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon

1 reference

7 January 2021

Responding to organ failure in HIV-infected patients

1 reference

7 January 2021

A role for hepatitis C virus infection in type II cryoglobulinemia

1 reference

7 January 2021

Hepatitis in patients with end‐stage renal disease

1 reference

7 January 2021

Risk of death among chronic dialysis patients infected with hepatitis C virus

1 reference

7 January 2021

Treatment of chronic hepatitis C with interferon alpha in patients on maintenance hemodialysis

1 reference

7 January 2021

Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years

1 reference

7 January 2021

Impact of hepatitis B and C virus on kidney transplantation outcome

1 reference

7 January 2021

Interferon alfa-2b in mixed cryoglobulinaemia: a controlled crossover trial

1 reference

7 January 2021

Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus

1 reference

7 January 2021

Acute exacerbation of vasculitis during interferon-alpha therapy for hepatitis C-associated cryoglobulinaemia

1 reference

7 January 2021

Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy

1 reference

7 January 2021

Hepatitis C and renal disease: an update

1 reference

7 January 2021

Liver damage in hemodialysis patients with hepatitis C virus viremia: a prospective 10-year study

1 reference

7 January 2021

Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study

1 reference

7 January 2021

Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis.

1 reference

7 January 2021

Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection.

1 reference

7 January 2021

Interferon treatment for chronic hepatitis C virus infection in uremic patients

1 reference

7 January 2021

Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment

1 reference

7 January 2021

The tolerance and efficacy of interferon‐α in haemodialysis patients with HCV infection: a multicentre, prospective study

1 reference

7 January 2021

Effect of interferon-alpha treatment in hemodialysis patients and renal transplant recipients with chronic hepatitis C.

1 reference

7 January 2021

Interferon-alpha in chronic hepatitis C infection in dialysis patients

1 reference

7 January 2021

Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B

1 reference

7 January 2021

Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection

1 reference

7 January 2021

Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B

1 reference

7 January 2021

Treatment of patients with hepatitis C virus on the waiting list

1 reference

7 January 2021

A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation

1 reference

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

1 reference

7 January 2021

Recombinant human erythropoietin in the treatment of anemic patients with hematological malignancies

1 reference

7 January 2021

Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients

1 reference

7 January 2021

The use of epoetin alfa in chemotherapy patients: a consistent profile of efficacy and safety

1 reference

7 January 2021

Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, an

1 reference

7 January 2021

Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group

1 reference

7 January 2021

Hepatitis C and liver transplantation

1 reference

7 January 2021

Chronic hepatitis C after renal transplantation. Treatment with alpha-interferon

1 reference

7 January 2021

Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial

1 reference

7 January 2021

The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation

1 reference

7 January 2021

Prophylaxis against HCV recurrence after liver transplantation: effect of interferon and ribavirin combination.

1 reference

7 January 2021

Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation

1 reference

7 January 2021

A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C.

1 reference

7 January 2021

Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.

1 reference

7 January 2021

Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy

1 reference

7 January 2021

Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation

1 reference

7 January 2021

Retransplantation for recurrent hepatitis C

1 reference

7 January 2021

Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection

1 reference

7 January 2021

High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study

1 reference

7 January 2021

Treatment of acute hepatitis C with interferon alfa-2b

1 reference

7 January 2021

Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance

1 reference

7 January 2021

Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?

1 reference

7 January 2021

Patterns of improvement after methadone treatment: 1 year follow-up results from the National Treatment Outcome Research Study.

1 reference

7 January 2021

Treating hepatitis C in methadone maintenance patients: an interim analysis

1 reference

7 January 2021

Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups

1 reference

7 January 2021

Protection against persistence of hepatitis C.

1 reference

7 January 2021

Lack of Protective Immunity Against Reinfection with Hepatitis C Virus

1 reference

7 January 2021

Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection

1 reference

7 January 2021

Second infection with a different hepatitis C virus genotype in a intravenous drug user during interferon therapy

1 reference

7 January 2021

Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment

1 reference

7 January 2021

Treatment of hepatitis C infection in injection drug users

1 reference

7 January 2021

Impact of alcohol on the histological and clinical progression of hepatitis C infection

1 reference

7 January 2021

Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis

1 reference

7 January 2021

Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study

1 reference

7 January 2021

Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C.

1 reference

7 January 2021

Intrahepatic hepatitis C virus replication is increased in patients with regular alcohol consumption

1 reference

7 January 2021

Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection

1 reference

7 January 2021

Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis

1 reference

7 January 2021

Contribution of obesity to hepatitis C-related fibrosis progression

1 reference

7 January 2021

Fulminant Hepatitis Associated with Hepatitis A Virus Superinfection in Patients with Chronic Hepatitis C

1 reference

7 January 2021

Independent and additive effect modification of hepatitis C and B viruses infection on the development of chronic hepatitis

1 reference

7 January 2021

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15057920

Identifiers

2 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15057920

PubMed publication ID

2 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017